Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 7,052 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Bipolar Disorder
Interventions: Omega-3 Supplementation, Psychoeducational Psychotherapy (PEP), Placebo; Drug · Behavioral · Other
Lead sponsor: L. Eugene Arnold; Other
Eligibility: 7 Years to 14 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: COVID-19
Interventions: Experimental Group, Placebo Group; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Relapsing Multiple Sclerosis
Interventions: SAR442168, Placebo, Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Cullman, Alabama • Maitland, Florida • Sunrise, Florida + 6 more

Conditions: Body Composition, Performance Measures, Hormone Profiles, Blood Lipid Profiles
Interventions: Shroom Tech Sport, Placebo; Dietary Supplement
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Parkinson Disease, Tremor
Interventions: Placebo, Suvecaltamide; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 18 more

Conditions: Covid19, SARS-CoV Infection
Interventions: Metformin, Placebo, Fluvoxamine, Ivermectin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 30 Years to 85 Years
Enrollment: 1,323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Sylmar, California • Aurora, Colorado • Golden, Colorado + 3 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Andecaliximab, Placebo to match Andecaliximab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Buffalo, New York + 1 more

Conditions: Systemic Sclerosis
Interventions: GLPG1690, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Los Angeles, California • Boca Raton, Florida • Boston, Massachusetts + 3 more

Conditions: Patients, Resistant Hypertension
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Birmingham, Alabama • North Hollywood, California • Atlantis, Florida + 4 more

Conditions: Heart Failure
Interventions: Clonidine Patch, Matching Placebo Patch; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia
Interventions: ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more

Conditions: Inflammatory Bowel Disease
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 19 Years to 90 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Hyperglycaemia (Diabetic)
Interventions: Dichloroacetate, Placebo oral capsule; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Anorexia Nervosa
Interventions: olanzapine, placebo; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 12 Years to 23 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Huntington's Disease
Interventions: PF-02545920, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more

Conditions: Sepsis, Kidney Injury, Thiamine Deficiency
Interventions: Thiamine Hydrochloride, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Manhasset, New York • New York, New York + 1 more

Conditions: Osteopenia, Osteoporosis
Interventions: alendronate sodium, placebo comparator; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Smoking Cessation
Interventions: Varenicline, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Los Angeles, California • DeLand, Florida • Lexington, Kentucky + 4 more

Conditions: Glioblastoma
Interventions: Galunisertib, Lomustine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 5
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more

Conditions: Phenylketonuria
Interventions: JNT-517, JNT-517 Matching Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 7 more

Conditions: Obesity or Overweight
Interventions: Placebo, Enicepatide; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 44
States / cities: Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 37 more

Conditions: Social Anxiety Disorder
Interventions: Pristiq, Placebo; Drug
Lead sponsor: The Medical Research Network; Other
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Essential Tremor
Interventions: SAGE-324, SAGE-324 Placebo; Drug
Lead sponsor: Sage Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 27
States / cities: Phoenix, Arizona • Rogers, Arkansas • Fresno, California + 23 more

Conditions: Non-relapsing Secondary Progressive Multiple Sclerosis
Interventions: Tolebrutinib, Placebo to match Tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 51
States / cities: Birmingham, Alabama • Phoenix, Arizona • Arcadia, California + 44 more

Search by objective public record fields.

Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified

Atovaquone for Treatment of COVID-19

Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Effects of Shroom Tech Sport Supplementation and Concurrent Training

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

Using Clonidine to Improve Leg Weakness in People With Heart Failure

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes

Olanzapine in the Treatment of Anorexia Nervosa

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

Thiamine as a Renal Protective Agent in Septic Shock

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider

A Study in Recurrent Glioblastoma (GB)

A Study of JNT-517 in Participants With Phenylketonuria (PKU)

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder

A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)